The advent of IBTs marks an unprecedented shift in obesity management paradigms. These agents operate by modulating incretin hormone pathways, influencing appetite regulation, insulin secretion, and glucose homeostasis. Despite their transformative impact on weight reduction, the therapies are not devoid of risks, necessitating refined clinical protocols to mitigate adverse effects and maximize therapeutic gains. As these medications become more widespread, healthcare providers face the formidable challenge of balancing efficacy with the maintenance of patients’ nutritional integrity and psychological well-being.

Central to the consensus is the role of medical nutritional therapy (MNT), a critical adjunct to pharmacotherapeutics. Delivered by registered dietitians, MNT encompasses tailored dietary guidance that ensures adequate protein, micronutrient, and vitamin intake—elements essential for preserving muscle mass and preventing malnutrition amid substantial weight loss. Moreover, dietitians play a crucial role in individualized dose-scaling of obesity drugs, attenuating gastrointestinal side effects such as nausea and vomiting, which are common barriers to adherence. Importantly, the consensus emphasizes the delivery of MNT within a framework of weight-inclusive and empowering communication, recognizing that health transcends mere numerical values on the scale.

The intersection of obesity treatment and mental health forms another pillar of this comprehensive statement. While IBTs have been associated with improved psychological outcomes, patients often enter treatment with pre-existing vulnerabilities including anxiety, depression, or eating disorders. The document calls for vigilant mental health screening and monitoring by multidisciplinary teams, integrating psychological expertise to identify and address the re-emergence or exacerbation of mental health issues during the transformative process of significant weight loss. Special attention is drawn to screening for alcohol use disorders prior to GLP-1 therapy initiation due to potential pharmacodynamic interactions.

Clinicians are urged to adopt more sophisticated monitoring beyond traditional metrics such as body mass index (BMI). Emerging evidence highlights that approximately 24-30% of weight lost via IBTs corresponds to fat-free mass, predominantly muscle tissue, which may have profound implications for physical function and metabolic health, especially in older adults at heightened risk for sarcopenia. The consensus proposes a pragmatic target of an approximate 3:1 ratio favoring fat loss over lean mass depletion. To facilitate this, advanced body composition assessments, including dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA), alongside functional measures like handgrip strength and sit-to-stand tests, are recommended where resources permit, reinforcing the shift toward personalized and functionally oriented evaluations.

The profound importance of physical activity is underscored, with a dual focus on aerobic exercise to augment weight loss and resistance training to preserve muscular integrity. These physical interventions synergize with IBTs and MNT, preventing excessive lean mass loss while simultaneously enhancing metabolic and psychological health. The consensus highlights the necessity of patient education to foster sustainable engagement in physical activity as an integral component of obesity care pathways.

Addressing the socioeconomic disparities that permeate obesity treatment access surfaces as a critical concern. Minority ethnic communities and socioeconomically disadvantaged groups disproportionately bear the burden of obesity yet often encounter substantial barriers, including limited access to IBTs and specialist nutritional services. The consensus highlights the pernicious effects of prescription regulations favoring patients with obesity-related complications over those without, perpetuating stigma and impeding early intervention strategies. It advocates for policy reforms to expand coverage for obesity pharmacotherapies and for healthcare systems to bolster equitable access to dietitian-led MNT, potentially narrowing health disparities and improving adherence and clinical outcomes.

Despite the transformative potential of IBTs, the authors illuminate significant lacunae in research, particularly concerning the long-term nutritional, functional, and psychological impacts of these treatments. A systematic review of 417 randomized controlled trials revealed that nutritional intake and biomarker reporting are sparse, with fewer than 5% assessing bone health, micronutrient status, or physical function. Such gaps hinder comprehensive safety profiling and limit evidence-based guidelines.

To address these deficiencies, the consensus delineates an ambitious research agenda. Priorities include establishing core outcome sets for IBT trials to standardize reporting; developing malnutrition screening tools tailored to obesity contexts; rigorous evaluation of muscle function and performance metrics; and investigating optimal protein intake protocols to safeguard lean tissue during therapy. Psychological outcomes require dedicated attention, alongside innovations in dose titration to reduce gastrointestinal side effect-induced discontinuations. Pharmacokinetic safety assessments and mixed-methods studies capturing real-world patient experiences, including post-cessation and post-bariatric surgery contexts, are also urgently needed.

In concluding, the statement proclaims IBTs as emblematic of a paradigm shift in obesity treatment, necessitating the integration of dietitian-led MNT with psychological and functional support frameworks. Key therapeutic goals revolve around mitigating gastrointestinal adverse effects, preempting micronutrient deficiencies, and preserving lean mass through nutrient-dense diets enriched in protein, fiber, and fluids, complemented by targeted supplementation and resistance exercise. Emphasis is placed on holistic care that attends to identity transformation, coping mechanisms, and potential disordered-eating patterns, all grounded in respectful and inclusive patient engagement.

As obesity emerges increasingly recognized as a chronic disease requiring multifaceted management, this consensus represents a seminal step toward harmonizing pharmacological advances with nutritional science, psychological insight, and functional rehabilitation. The future of obesity care hinges on such integrative approaches, driven by patient-centered research and equitable healthcare delivery systems that transcend stigma and structural barriers.

Subject of Research: Use of incretin-based therapies in obesity treatment and associated nutritional, functional, and psychological considerations.

Article Title: New Consensus on Optimizing Obesity Drug Use Emphasizes Nutrition, Mental Health, and Functional Support

News Publication Date: 2026 (at European Congress on Obesity)

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: Obesity treatment, incretin-based therapies, GLP-1 receptor agonists, medical nutritional therapy, body composition, muscle mass preservation, psychological health, physical activity, socioeconomic disparities, obesity pharmacotherapy, consensus statement

Ozempic, known chemically as semaglutide, functions as a glucagon-like peptide-1 (GLP-1) receptor agonist to regulate blood glucose levels in diabetic patients. However, its off-label usage—particularly as a weight-loss intervention—has gained viral attention fueled by anecdotal testimonials, influencer endorsements, and peer exchanges on networks such as Twitter, Instagram, and TikTok. This phenomenon reflects the capacity of social media to disseminate medical narratives detached from conventional regulatory verifications, thereby creating novel health discourses. The study harnesses qualitative content analysis methodologies to map thematic patterns and rhetorical strategies employed in these online conversations.

One of the central insights of Kartal and Günaltay’s research is the way social media facilitates an alternative construction of drug legitimacy. Unlike traditional biomedical paradigms grounded in randomized control trials and regulatory approvals, social media deploys experiential knowledge as a source of authority. Users share personal success stories, often accompanied by before-and-after imagery, effectively creating persuasive narratives that frame Ozempic as a transformative tool for weight management and enhanced self-image. This shift foregrounds subjectivity and lived experience over clinical endorsement, democratizing but also complicating health knowledge dissemination.

The study delves into the communicative mechanisms by which Ozempic off-label use is normalized and valorized online. Hashtags, viral challenges, and meme culture play critical roles in embedding the drug within lifestyle discourses. This reframing from solely a medical intervention to a desirable aesthetic enhancement intersects with broader sociocultural trends prioritizing slimness and health optimization. The research highlights how the symbolic capital accrued through participation in such digital communities reinforces drug desirability, thereby potentially influencing patterns of pharmaceutical demand and self-medication practices.

Importantly, Kartal and Günaltay address the ethical and public health implications arising from this social construction. Off-label consumption without medical supervision carries inherent risks, including adverse side effects and interactions which may not be fully understood by lay consumers. The viral spread of unregulated health claims can undermine public trust in healthcare systems and regulatory bodies, complicating efforts to ensure safe medication practices. This tension reflects a critical challenge in contemporary pharmacoepidemiology where digital culture and medical governance intersect.

From a methodological perspective, the authors utilize discourse analysis to critically engage with the linguistic and visual modalities that constitute Ozempic’s online portrayal. The analysis reveals a nuanced interplay between persuasive rhetoric, affective appeals, and visual semiotics that collectively function to establish Ozempic’s desirability beyond its indicated use. This multimodal approach allows the study to capture the complexity and dynamism of online health narratives in a way that quantitative methods may overlook.

The study also situates the Ozempic social media phenomenon within a broader historical context of off-label innovation and pharmaceutical repurposing. While off-label prescribing is a longstanding clinical practice often motivated by unmet therapeutic needs, the digital age has transformed this landscape by enabling direct-to-consumer dissemination of drug information. This shift raises important questions about the evolving boundaries between clinical authority and consumer agency in medical decision-making.

Kartal and Günaltay’s findings offer valuable insights for healthcare professionals, policymakers, and social scientists interested in the intersections of medication use, digital culture, and public health. Their work advocates for proactive engagement with social media discourse as part of public health strategy, recognizing platforms as vital yet challenging arenas for health communication. Monitoring and dialoguing with online communities could facilitate more informed and responsible usage of medications such as Ozempic in off-label contexts.

The research underscores the necessity for enhanced digital literacy initiatives that equip consumers with critical tools to evaluate health information encountered on social media. The viral allure of Ozempic’s off-label benefits needs to be counterbalanced by accessible, evidence-based guidance on potential risks and contraindications. Health communication strategies must adapt to the fragmented and often contradictory nature of online medical information ecosystems to safeguard individual and public wellbeing.

Furthermore, the study raises important considerations regarding pharmaceutical companies’ roles in the propagation or containment of off-label discourse. While strict regulatory frameworks limit promotional activities, pharmaceutical entities cannot entirely control user-generated content on social media. This reality demands nuanced regulatory and corporate social responsibility approaches that consider the mediated landscapes where medical knowledge circulates.

Intriguingly, the research also points to the affective dimensions driving Ozempic’s popularity. Beyond weight loss, users frequently associate the drug with enhanced self-esteem, social acceptance, and aspirational identities. This emotional investment fuels continued engagement with off-label narratives and propels the drug’s viral dissemination, illustrating how pharmaceutical consumption intersects with psychosocial dimensions of health and identity.

Kartal and Günaltay propose that this case study can serve as a template for analyzing other emerging pharmacological discourses within digital milieus. The dynamic and participatory nature of social media communication demands interdisciplinary frameworks that integrate sociological, medical, and communication science perspectives to comprehensively address the challenges posed by off-label drug social construction.

In conclusion, the study presented by Kartal and Günaltay marks a critical contribution to understanding how contemporary social media environments reconstruct the meanings and uses of pharmaceutical agents such as Ozempic. Through empirical and theoretical rigor, it illuminates the intricate processes by which off-label drug use becomes socially constructed and widely adopted beyond traditional medical oversight. This phenomenon invites ongoing scholarly attention and strategic public health responses in an increasingly digitized pharmaco-epistemic landscape.

As the boundaries between formal medical practice and informal health communication continue to blur, insights from this study foreground the urgency of informed, contextualized engagement with social media-driven health phenomena. Ozempic’s trajectory from diabetes treatment to viral weight-loss agent exemplifies the transformative power of social narratives in shaping drug use behaviors and highlights the evolving challenges of safe and ethical pharmacotherapy in the digital age.

Subject of Research: The social construction and discourse of off-label Ozempic drug use on social media platforms.

Article Title: The Social Construction of Off-label Drug Use: A Case Study of Ozempic Discourse on Social Media.

Article References:
Kartal, N., Günaltay, M.M. The Social Construction of Off-label Drug Use: A Case Study of Ozempic Discourse on Social Media. Int J Ment Health Addiction (2025). https://doi.org/10.1007/s11469-025-01599-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11469-025-01599-8